A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
This multi-center observational study will evaluate the use and efficacy of RoActemra/Actemra
(tocilizumab) in patients with moderate to severe rheumatoid arthritis. Eligible patients
initiated on RoActemra/Actemra treatment according to the licensed label will be followed for
6 months.